FDA analysis: Drug prices plunge with generics competition

04/4/2006 | NYTimes.com

Competition from generics substantially reduces the prices of prescription drugs, according to an analysis by the FDA. A single challenger to a branded drug typically sells for 94% of its rival's price, but when two generics are on the market the average price drops to 52% of the name-brand's version. Prices continue to decline with even more competition, although at a slower pace, the analysis found.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY